Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
27 Results for "
vancomycin-resistant Staphylococcus aureus
" in MedChemExpress (MCE) Product Catalog:
Products (27)
27 Results for "vancomycin-resistant Staphylococcus aureus" in MCE Product Catalog:
Cat. No.: HY-A0279
CAS No.: 270076-60-3
Synonyms: Pristinamycine
Category:
Infection Microorganisms Macrolide Antibiotics Antibiotics Disease Research Antibacterial Disease Research Fields
Target:
Synonyms: PNU-100592
Target:
Research Areas:
Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol (HY-B0239) and lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
Cat. No.: HY-N10765
CAS No.: 120278-22-0
Target:
Cat. No.: HY-123779
CAS No.: 193282-45-0
RWJ-49815 is a histidine kinase inhibitor. RWJ-49815 inhibits the autokinase activity of purified GST-Sln1 and the autophosphorylation of KinA in vitro. RWJ-49815 acts as a fungal growth inhibitor . RWJ-49815 serves as a bactericide against Gram-positive pathogenic bacteria. RWJ-49815 is applicable to research related to fungal infections and Gram-positive bacterial infections .
KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells .
Cat. No.: HY-156198
CAS No.: 15005-62-6
Category:
Target:
Cat. No.: HY-143326
CAS No.: 2413865-92-4
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
Cat. No.: HY-N16446
CAS No.: 345295-46-7
Category:
Target:
Cat. No.: HY-174273
Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections .
Cat. No.: HY-W033728
CAS No.: 12080-32-9
Platinum(COD)dichloride (Compound Pt1) is an Antibacterial agent. Platinum(COD)dichloride shows antibacterial activity against a panel of gram-positive bacteria including Vancomycin (HY-B0671) and Methicillin (HY-121544) resistant Staphylococcus aureus .
Cat. No.: HY-N14899
CAS No.: 484675-06-1
Category:
Target:
Cat. No.: HY-122174
CAS No.: 432038-96-5
Synonyms: CP-5609
Target:
Research Areas:
ME-1036 (CP-5609) is a carbapenem antibiotic. ME-1036 against resistant Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE), and ESBL-producing E. coli and K. pneumoniae but is not effective against P. aeruginosa .
Cat. No.: HY-161263
Antibacterial agent 182 (compound 8c) is an antibacterial agent that shows antibacterial activity against various Gram-positive bacteria, particularly against Vancomycin-resistant Enterococcus faecalis (MIC ≤0.125 μg/mL). Antibacterial agent 182 inhibits biofilm formation of Staphylococcus aureus and Pseudomonas aeruginosa at sub-MIC doses .
Cat. No.: HY-173225
MRSA/VRE-IN-1 (Compound 3e) is an inhibitor against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The MIC/MBC of MRSA/VRE-IN-1 against VRE is 3.6/7.3 µM, and against MRSA is 7.3/14.6 µM. MRSA/VRE-IN-1 can be used in the research of the anti-infection field .
Cat. No.: HY-N15019
CAS No.: 158446-31-2
Category:
Target:
Cat. No.: HY-N14171
CAS No.: 62256-05-7
Category:
Cat. No.: HY-12770R
CAS No.: 14367-47-6
Synonyms: Mebeverine metabolite Mebeverine alcohol (Standard)
Target:
Research Areas:
Mebeverine alcohol (Standard) is an analytical standard for Mebeverine alcohol. This product is intended for research and analytical applications. Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of Chloramphenicol (HY-B0239) and Lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
Cat. No.: HY-182798
Research Areas:
Antibacterial agent 337 is an antibacterial agent. Antibacterial agent 337 specifically interacts with PG in bacterial cell membranes, triggering membrane disruption, membrane depolarization, increased permeability, cytoplasmic leakage, ROS accumulation and rapid bacterial death. Antibacterial agent 337 inhibits biofilm formation and disrupts mature biofilms. Antibacterial agent 337 exhibits potent in vivo antibacterial efficacy in a mouse model of Staphylococcus aureus skin abscess. Antibacterial agent 337 can be used in studies of Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus infections, vancomycin-resistant Enterococcus faecalis infections and bacterial biofilm infections .
Cat. No.: HY-N14172
CAS No.: 69176-72-3
Category:
Cat. No.: HY-69174
CAS No.: 228862-97-3
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
